Based on the above mechanisms, bevacizumab, the humanized anti-human VEGF-A monoclonal antibody, was combined with B6.H12, an anti-CD47 antibody, to assesse the anti-tumor effects of VEGF/CD47 dual targeting therapy. This evidence concerns the gene CD47 and neoplasm.